Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Pfizer
Sumitomo Pharma America, Inc.
NextCure, Inc.
OncoNano Medicine, Inc.
Herlev Hospital
Ludwig Institute for Cancer Research
Incyte Corporation
Duke University
Incyte Corporation
Eisai Inc.